Catalyst
Slingshot members are tracking this event:
Rezolute, Inc.(RZLT) Phase 2b RIZE study of RZ358 for the treatment of congenital hyperinsulinism (CHI) top line data expected in the second half of 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RZLT | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 22, 2021
Occurred Source:
https://ir.rezolutebio.com/press-releases/detail/290/rezolute-presents-results-from-two-week-natural-history
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rz358, Rize, Congenital Hyperinsulinism
